1,6-Anhydro-B-D-glucose 2,3,4-tribenzoat E | 5334-19-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1,6-Anhydro-B-D-glucose 2,3,4-tribenzoat E
• 英文别名: (3,4-dibenzoyloxy-6,8-dioxabicyclo[3.2.1]octan-2-yl) benzoate
• CAS: 5334-19-0
• 化学式: C₂₇H₂₂O₈
• 分子量: 474.5
• InChiKey: PUALUCOESOGESO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  97.4
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• [EN] PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY<br/>[FR] DISACCHARIDES HEPTASULFATÉS PURS À BIODISPONIBILITÉ ORALE AMÉLIORÉE
  申请人：OPKO PHARMACEUTICALS LLC

  公开号：WO2018035050A1

  公开（公告）日：2018-02-22

  Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The heptasulfated disaccharides administered orally have comparable bioavailability to the intravenous administered dosage form.

  披露了具有用于哮喘或哮喘相关障碍的用途的过硫酸盐双糖。经口服给药的七硫酸盐双糖与静脉给药剂型的生物利用度相当。
• Pure heptasulfated disaccharides having improved oral bioavailability
  申请人：OPKO Pharmaceuticals, LLC.

  公开号：US10829509B2

  公开（公告）日：2020-11-10

  Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The heptasulfated disaccharides administered orally have comparable bioavailability to the intravenous administered dosage form.

  本研究公开了可用于治疗哮喘或哮喘相关疾病的七硫化二糖。口服七硫化二糖的生物利用度与静脉注射剂型相当。
• PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY
  申请人：OPKO Pharmaceuticals, LLC

  公开号：US20210009620A1

  公开（公告）日：2021-01-14

  Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The heptasulfated disaccharides administered orally have comparable bioavailability to the intravenous administered dosage form.